TransCode Therapeutics, Inc. (RNAZ) earnings
RNAZ earnings moved a median of -2.03% by the close. Quarterly and annual RNAZ reports and results, each read against the price at its own news timestamp. Back to the RNAZ overview →
17 measured RNAZ earnings events.
Where these RNAZ earnings landedvs 17 measured RNAZ earnings reactions
| Middle 50% of RNAZ earnings reactions | -7.27% to +4.56% |
|---|---|
| Median reaction (to close) | -2.03% |
| Measured reactions | 17 |
Point-in-time · zero look-ahead
Half of the 17 RNAZ earnings events with a measured close landed between -7.27% and +4.56%; 47% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Transcode Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -7.49% | -5.95% | |
| Form 10-Q Transcode Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | — | -6.51% | |
| Form 10-K/A Transcode Therapeutics, For: Dec 31 | SEC filing · Form 10-K | — | -4.69% | |
| Form 10-K Transcode Therapeutics, For: Dec 31 | SEC filing · Form 10-K | — | -2.03% | |
| Form NT 10-K Transcode Therapeutics, For: Dec 31 | SEC filing · Form NT | — | +1.40% | |
| Form 10-Q Transcode Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.00% | +4.56% | |
| Form 10-Q Transcode Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -4.87% | -7.78% | |
| Form 10-Q Transcode Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +0.31% | -7.27% | |
| Form 10-K/A Transcode Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +18.25% | +17.94% | |
| Form 10-K Transcode Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -4.12% | -8.80% | |
| Form NT 10-K Transcode Therapeutics, For: Dec 31 | SEC filing · Form NT | +1.29% | +14.16% | |
| Form 10-Q Transcode Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +3.33% | +0.09% | |
| Form 10-Q Transcode Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +2.21% | +8.27% | |
| Form 10-Q Transcode Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +1.00% | +10.60% | |
| Form 10-K Transcode Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +2.65% | +1.62% | |
| Form 10-Q Transcode Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.03% | -8.18% | |
| TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update | Press release | +0.03% | -8.18% |
Keep exploring
More RNAZ: analyst actions → · SEC filings → · RNAZ overview →